Ginkgo biloba in the treatment of autistic disorder

A double - blind placebo controlled trial of Ginkgo Biloba added to risperidone in patint with autistic disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201012031556N19

Enrollment

Registered

2010-12-04

Start date

2010-04-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood autism. Childhood autism

Interventions

Intervention 1: Tablet Ginkgo biloba 80-120 mg/day+ Tablet Risperidon 1-3.5 mg as intervention. Intervention 2: Tablet Risperidone 1-3.5 mg/day +Tablet Placebo as control.

Treatment - Drugs

Placebo

Tablet Ginkgo biloba 80-120 mg/day+ Tablet Risperidon 1-3.5 mg as intervention

Tablet Risperidone 1-3.5 mg/day +Tablet Placebo as control

Eligibility

Sex/Gender

All

Age

3 Years to 12 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: DSM IV clinical diagnosis of autism, children and adolescents between the ages of 3 and 12 years (inclusive), Exclusion Criteria: Presence of any active medical problem, any diagnosis in Axis I and II except for mental retatdation, history of allergy to Ginkgo Biloba, receiving any psychotropic medications during past two weeks prior to the trial

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of Autism. Timepoint: Baseline and weerks 2, 4, 6, 8, 10. Method of measurement: Aberrant Behavior Checklist-Community (ABC-C) Rating Scale.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026